Issue 18.1
CASE STUDY: Better safe than sorry when handling sensitive products
This case study details Schubert-Pharma’s automated solution for a small-component packaging task. Read more
That’s a wrap! What should be considered when deciding on the best coating tech?
Various aspects must be considered when deciding upon the best coating technology. Here, the authors describe their recent study comparing three different coating technologies’ efficiency in a pellet coating process. Read more
Pharma’s Fantastic Four — what to watch out for over the coming 12 months in pharma
What to watch out for over the coming 12 months that should have an impact on the pharma landscape, according to some industry leaders… Read more
Needle in a haystack! What tech advances are shaping drug development?
Drug research and development is often likened to finding a needle in a haystack with multiple targets and many potential variables with which they can interact. So, what technological advancements are impacting development timelines… Read more
End-to end solution for continuous production of drug implants
We sit down with Dirk Leister, technical marketing manager, Thermo Fisher Scientific, to find out more about hot melt extrusion and the company’s new automated, integrated system designed for continuous production of drug implants. Read more
Potential impacts of Brexit on the pharma regulatory landscape
In this article, NSF International goes into detail about what the potential ramifications of Brexit may be on the regulatory landscape in pharma. Read more
Did you know? Tips and tricks on how to implement serialisation solutions
Here, Dan Anslow, UK sales manager, Crest Solutions, shares some key tips and insights, learned through partnering with pharmaceutical manufacturers that have already successfully implemented solutions for serialisation, aggregation and Track & Trace Read more
Brexit update: Regulatory developments within pharma
Here, Vikash Patel, senior regulatory specialist for ELC Group, gives us an update on the regulatory developments impacting the pharma industry as a result of Brexit. Read more
Sowing the seeds of consistency: What to consider with plant-based pharma ingredients
In this article, Hervé Sibillat, general manager, ADM-SIO, discusses the important considerations in managing the natural variability of plant-based pharmaceutical ingredients. Read more
Strategic measurements — how and where these can help in the Life Sciences industrial strategy
In this article, Michael Adeogun, head of Life Sciences and Health at NPL examines how and where measurement can help government and industry grasp the opportunities the Strategy and Sector Deal offer. Read more
Insulin online? Five reasons why ecommerce is getting bigger in healthcare
All signs are that the life sciences and healthcare market is ripe for disruption, with ecommerce coming into its own in the sector. Scott Allison, president Life Sciences & Healthcare, DHL, lists five reasons as to why it is happening now. Read more
Time to get serious about avoiding operational downtime
Avoiding operational downtime is a major issue for all organisations, as the related disruption and financial consequences can prove catastrophic. Here, Tim Wynn-Jones suggests that organisations need to start taking it seriously. Read more
Tech talk no.1: Seven tips to success for mHealth
In the first of the Tech Talk series, Novarum founder and BBI group head of mobile, Dr Neil Polwart, goes through his seven key tips that should be kept at front of mind when trying to implement a successful mHealth strategy. Read more
The next level in pharma glass quality, how the perfeXion initiative can help
About a year ago, Schott set out to elevate pharmaceutical glass quality to a new level with its perfeXion initiative. EPM sat down with Dr Patrick Markschläger, Schott Tubing, to discuss the impact of glass tubing on future packaging challenges. Read more
Shot in the dark: Why does the flu vaccine vary and is there an alternative approach?
As we embark on a difficult flu season, I look at why infection rates vary so much year on year and the potential universal vaccine one company is progressing through the clinical development stages. Read more
